Clinical Edge Journal Scan

Key clinical point: In this meta-analysis, migraine was more frequent among patients with vs without epilepsy and epilepsy was more frequent among patients with vs without migraine, highlighting a co-morbid association between migraine and epilepsy.

Major finding: The lifetime prevalence of migraine was 80% higher in patients with epilepsy compared with those without epilepsy (odds ratio [OR]/relative risk [RR] 1.80; P < .001). Similarly, the lifetime prevalence of epilepsy was 80% higher in patients with migraine compared with those without migraine (OR/RR 1.80; P < .001).

Study details: The data come from a meta-analysis of 13 studies that evaluated the association between migraine and epilepsy.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Wu X and Zhuang J. Association between migraine and epilepsy: A meta-analysis. Front Neurol. 2024;14:1276663 (Jan 5). doi: 10.3389/fneur.2023.1276663

Key clinical point: In this meta-analysis, migraine was more frequent among patients with vs without epilepsy and epilepsy was more frequent among patients with vs without migraine, highlighting a co-morbid association between migraine and epilepsy.

Major finding: The lifetime prevalence of migraine was 80% higher in patients with epilepsy compared with those without epilepsy (odds ratio [OR]/relative risk [RR] 1.80; P < .001). Similarly, the lifetime prevalence of epilepsy was 80% higher in patients with migraine compared with those without migraine (OR/RR 1.80; P < .001).

Study details: The data come from a meta-analysis of 13 studies that evaluated the association between migraine and epilepsy.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Wu X and Zhuang J. Association between migraine and epilepsy: A meta-analysis. Front Neurol. 2024;14:1276663 (Jan 5). doi: 10.3389/fneur.2023.1276663

Key clinical point: In this meta-analysis, migraine was more frequent among patients with vs without epilepsy and epilepsy was more frequent among patients with vs without migraine, highlighting a co-morbid association between migraine and epilepsy.

Major finding: The lifetime prevalence of migraine was 80% higher in patients with epilepsy compared with those without epilepsy (odds ratio [OR]/relative risk [RR] 1.80; P < .001). Similarly, the lifetime prevalence of epilepsy was 80% higher in patients with migraine compared with those without migraine (OR/RR 1.80; P < .001).

Study details: The data come from a meta-analysis of 13 studies that evaluated the association between migraine and epilepsy.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Wu X and Zhuang J. Association between migraine and epilepsy: A meta-analysis. Front Neurol. 2024;14:1276663 (Jan 5). doi: 10.3389/fneur.2023.1276663

Key clinical point: Erenumab demonstrated a more favorable efficacy profile than rimegepant for the prevention of episodic and chronic migraine.

Major finding: Compared with 75 mg rimegepant, 70 mg erenumab significantly reduced monthly migraine days (MMD) by 0.90 days at 3 months (P = .042) and 140 mg erenumab significantly reduced MMD by 0.94 (P = .014) and 1.28 (P = .005) days at 1 month and 3 months, respectively. Erenumab showed advantages over rimegepant in improving Migraine-Specific Quality-of-life role function-restrictive domain and Migraine Disability Assessment scores (MIDAS) at 3 months.

Study details: This study performed anchored matching-adjusted indirect comparison of the relative efficacy of two erenumab regimens (70 mg and 140 mg) with rimegepant (75 mg) for migraine prevention using data from two phase 2/3 trials for erenumab (295 and STRIVE) and a phase 2/3 trial for rimegepant.

Disclosures: This study was funded by Novartis Healthcare Pvt. Ltd. Several authors declared being employees of and holding stocks or stock options in Novartis.

Source: Mahon R et al. Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison. J Comp Eff Res. 2024 (Jan 4). doi: 10.57264/cer-2023-0122

Key clinical point: Erenumab demonstrated a more favorable efficacy profile than rimegepant for the prevention of episodic and chronic migraine.

Major finding: Compared with 75 mg rimegepant, 70 mg erenumab significantly reduced monthly migraine days (MMD) by 0.90 days at 3 months (P = .042) and 140 mg erenumab significantly reduced MMD by 0.94 (P = .014) and 1.28 (P = .005) days at 1 month and 3 months, respectively. Erenumab showed advantages over rimegepant in improving Migraine-Specific Quality-of-life role function-restrictive domain and Migraine Disability Assessment scores (MIDAS) at 3 months.

Study details: This study performed anchored matching-adjusted indirect comparison of the relative efficacy of two erenumab regimens (70 mg and 140 mg) with rimegepant (75 mg) for migraine prevention using data from two phase 2/3 trials for erenumab (295 and STRIVE) and a phase 2/3 trial for rimegepant.

Disclosures: This study was funded by Novartis Healthcare Pvt. Ltd. Several authors declared being employees of and holding stocks or stock options in Novartis.

Source: Mahon R et al. Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison. J Comp Eff Res. 2024 (Jan 4). doi: 10.57264/cer-2023-0122

Key clinical point: Erenumab demonstrated a more favorable efficacy profile than rimegepant for the prevention of episodic and chronic migraine.

Major finding: Compared with 75 mg rimegepant, 70 mg erenumab significantly reduced monthly migraine days (MMD) by 0.90 days at 3 months (P = .042) and 140 mg erenumab significantly reduced MMD by 0.94 (P = .014) and 1.28 (P = .005) days at 1 month and 3 months, respectively. Erenumab showed advantages over rimegepant in improving Migraine-Specific Quality-of-life role function-restrictive domain and Migraine Disability Assessment scores (MIDAS) at 3 months.

Study details: This study performed anchored matching-adjusted indirect comparison of the relative efficacy of two erenumab regimens (70 mg and 140 mg) with rimegepant (75 mg) for migraine prevention using data from two phase 2/3 trials for erenumab (295 and STRIVE) and a phase 2/3 trial for rimegepant.

Disclosures: This study was funded by Novartis Healthcare Pvt. Ltd. Several authors declared being employees of and holding stocks or stock options in Novartis.

Source: Mahon R et al. Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison. J Comp Eff Res. 2024 (Jan 4). doi: 10.57264/cer-2023-0122

Key clinical point: Monoclonal antibodies targeting the anti-calcitonin gene-related peptide (CGRP) showed persistent and comparable outcomes within a real-world cohort of patients with migraine leading to a reduction in migraine days per month (MDM) among responders with large effect sizes; however, the response was influenced by genetic factors.

Major finding: Patients responding to anti-CGRP monoclonal antibodies demonstrated persistent reduction in MDM (usually ≥50% reduction from baseline) at first (η² = 0.26) and second (η² = 0.22) follow-up, with all treatments showing similar effects and large effect sizes. Non-responders vs responders had a lower mean genetic risk score (P = .041) without any difference in polygenic risk score.

Study details: This retrospective clinical and genetic study included 481 patients with migraine who were prescribed preventive erenumab (n = 166), galcanezumab (n = 164), or fremanezumab (n = 151).

Disclosures: This study was funded by the US Agency for Healthcare Research and Quality. S Meyers declared serving on the speakers’ bureau for Biohaven Pharmaceuticals and Allergan.

Source: Chase BA et al. Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study. Headache. 2023 (Dec 10). doi:

Key clinical point: Monoclonal antibodies targeting the anti-calcitonin gene-related peptide (CGRP) showed persistent and comparable outcomes within a real-world cohort of patients with migraine leading to a reduction in migraine days per month (MDM) among responders with large effect sizes; however, the response was influenced by genetic factors.

Major finding: Patients responding to anti-CGRP monoclonal antibodies demonstrated persistent reduction in MDM (usually ≥50% reduction from baseline) at first (η² = 0.26) and second (η² = 0.22) follow-up, with all treatments showing similar effects and large effect sizes. Non-responders vs responders had a lower mean genetic risk score (P = .041) without any difference in polygenic risk score.

Study details: This retrospective clinical and genetic study included 481 patients with migraine who were prescribed preventive erenumab (n = 166), galcanezumab (n = 164), or fremanezumab (n = 151).

Disclosures: This study was funded by the US Agency for Healthcare Research and Quality. S Meyers declared serving on the speakers’ bureau for Biohaven Pharmaceuticals and Allergan.

Source: Chase BA et al. Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study. Headache. 2023 (Dec 10). doi:

Key clinical point: Monoclonal antibodies targeting the anti-calcitonin gene-related peptide (CGRP) showed persistent and comparable outcomes within a real-world cohort of patients with migraine leading to a reduction in migraine days per month (MDM) among responders with large effect sizes; however, the response was influenced by genetic factors.

Major finding: Patients responding to anti-CGRP monoclonal antibodies demonstrated persistent reduction in MDM (usually ≥50% reduction from baseline) at first (η² = 0.26) and second (η² = 0.22) follow-up, with all treatments showing similar effects and large effect sizes. Non-responders vs responders had a lower mean genetic risk score (P = .041) without any difference in polygenic risk score.

Study details: This retrospective clinical and genetic study included 481 patients with migraine who were prescribed preventive erenumab (n = 166), galcanezumab (n = 164), or fremanezumab (n = 151).

Disclosures: This study was funded by the US Agency for Healthcare Research and Quality. S Meyers declared serving on the speakers’ bureau for Biohaven Pharmaceuticals and Allergan.

Source: Chase BA et al. Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study. Headache. 2023 (Dec 10). doi:

Key clinical point: Agomelatine appeared to be an effective preventive treatment for episodic migraine without aura.

Major finding: After 3 months of treatment, patients receiving agomelatine vs placebo had significant reduction in headache frequency (4.8 vs 5.82; P = .009) and severity (─4.1 vs ─0.71; P < .001), mean monthly migraine days (8.86 vs 10.63; P = .025), and Migraine Disability Assessment Score (MIDAS; ─1.06 vs ─0.36; P < .001).

Study details: Findings are from a parallel randomized controlled trial that included 99 patients with episodic migraine without aura who were randomly assigned to receive either agomelatine (n = 49) or placebo (vitamin B₁ tablets; n = 50).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Farzin K et al. The effectiveness of agomelatine on headache severity and frequency in episodic migraine without aura; a parallel randomized controlled trial study. BMC Neurol. 2024;24:2 (Jan 2). doi: 10.1186/s12883-023-03516-9

Key clinical point: Agomelatine appeared to be an effective preventive treatment for episodic migraine without aura.

Major finding: After 3 months of treatment, patients receiving agomelatine vs placebo had significant reduction in headache frequency (4.8 vs 5.82; P = .009) and severity (─4.1 vs ─0.71; P < .001), mean monthly migraine days (8.86 vs 10.63; P = .025), and Migraine Disability Assessment Score (MIDAS; ─1.06 vs ─0.36; P < .001).

Study details: Findings are from a parallel randomized controlled trial that included 99 patients with episodic migraine without aura who were randomly assigned to receive either agomelatine (n = 49) or placebo (vitamin B₁ tablets; n = 50).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Farzin K et al. The effectiveness of agomelatine on headache severity and frequency in episodic migraine without aura; a parallel randomized controlled trial study. BMC Neurol. 2024;24:2 (Jan 2). doi: 10.1186/s12883-023-03516-9

Key clinical point: Agomelatine appeared to be an effective preventive treatment for episodic migraine without aura.

Major finding: After 3 months of treatment, patients receiving agomelatine vs placebo had significant reduction in headache frequency (4.8 vs 5.82; P = .009) and severity (─4.1 vs ─0.71; P < .001), mean monthly migraine days (8.86 vs 10.63; P = .025), and Migraine Disability Assessment Score (MIDAS; ─1.06 vs ─0.36; P < .001).

Study details: Findings are from a parallel randomized controlled trial that included 99 patients with episodic migraine without aura who were randomly assigned to receive either agomelatine (n = 49) or placebo (vitamin B₁ tablets; n = 50).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Farzin K et al. The effectiveness of agomelatine on headache severity and frequency in episodic migraine without aura; a parallel randomized controlled trial study. BMC Neurol. 2024;24:2 (Jan 2). doi: 10.1186/s12883-023-03516-9

Key clinical point: Gut microbiota may have a potential casual association with migraine symptoms, with evidence indicating a connection between gut microbiota and increased or decreased risk for migraine.

Major finding: A higher abundance of genus Lactobacillus (inverse variance weighted [IVW] odds ratio [OR] 1.10; P = .004) and family Prevotellaceae (IVW OR 0.89; P = .02) were causally associated with a higher and lower risk for migraine, respectively.

Study details: This study used a two-sample Mendelian randomization framework to assess the causal effects of gut microbiota on migraine risk using 2651 single nucleotide polymorphisms as instrumental variables. Large-scale genome-wide association studies consisting of 18,340 participants from 24 cohorts provided the summary-level statistics for gut microbiota.

Disclosures: This study was funded by the National Key Research and Development Program. The authors declared no conflicts of interest.

Source: Meng X et al. Exploring the role of gut microbiota in migraine risk: A two-sample Mendelian randomization study. Scand J Gastroenterol. 2023 (Dec 27). doi: 10.1080/00365521.2023.2298370

Key clinical point: Gut microbiota may have a potential casual association with migraine symptoms, with evidence indicating a connection between gut microbiota and increased or decreased risk for migraine.

Major finding: A higher abundance of genus Lactobacillus (inverse variance weighted [IVW] odds ratio [OR] 1.10; P = .004) and family Prevotellaceae (IVW OR 0.89; P = .02) were causally associated with a higher and lower risk for migraine, respectively.

Study details: This study used a two-sample Mendelian randomization framework to assess the causal effects of gut microbiota on migraine risk using 2651 single nucleotide polymorphisms as instrumental variables. Large-scale genome-wide association studies consisting of 18,340 participants from 24 cohorts provided the summary-level statistics for gut microbiota.

Disclosures: This study was funded by the National Key Research and Development Program. The authors declared no conflicts of interest.

Source: Meng X et al. Exploring the role of gut microbiota in migraine risk: A two-sample Mendelian randomization study. Scand J Gastroenterol. 2023 (Dec 27). doi: 10.1080/00365521.2023.2298370

Key clinical point: Gut microbiota may have a potential casual association with migraine symptoms, with evidence indicating a connection between gut microbiota and increased or decreased risk for migraine.

Major finding: A higher abundance of genus Lactobacillus (inverse variance weighted [IVW] odds ratio [OR] 1.10; P = .004) and family Prevotellaceae (IVW OR 0.89; P = .02) were causally associated with a higher and lower risk for migraine, respectively.

Study details: This study used a two-sample Mendelian randomization framework to assess the causal effects of gut microbiota on migraine risk using 2651 single nucleotide polymorphisms as instrumental variables. Large-scale genome-wide association studies consisting of 18,340 participants from 24 cohorts provided the summary-level statistics for gut microbiota.

Disclosures: This study was funded by the National Key Research and Development Program. The authors declared no conflicts of interest.

Source: Meng X et al. Exploring the role of gut microbiota in migraine risk: A two-sample Mendelian randomization study. Scand J Gastroenterol. 2023 (Dec 27). doi: 10.1080/00365521.2023.2298370

Key clinical point: High-dose eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) supplementation demonstrated highest efficacy and acceptability among all studied treatments, emphasizing its potential as a first-choice treatment for migraine prophylaxis.

Major finding: Among all prophylactic treatments, high-dose EPA/DHA supplementation showed the highest decrease in migraine frequency (standardized mean difference [SMD] ─1.36; 95% CI ─2.32 to ─0.39) and severity (SMD ─2.23; 95% CI ─3.17 to ─1.30) and the most favorable acceptability rate (odds ratio 1.00; 95% CI 0.06 to 17.41) compared with placebo.

Study details: The data come from a network meta-analysis of 40 randomized controlled trials that included 6616 patients with either episodic or chronic migraine.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Tseng PT et al. Efficacy of high dosage anti-inflammatory eicosapentaenoic acid/docosahexaenoic acid for migraine prophylaxis: A network meta-analysis. Adv Nutr. 2023;15(2):100163 (Dec 16). doi: 10.1016/j.advnut.2023.100163

Key clinical point: High-dose eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) supplementation demonstrated highest efficacy and acceptability among all studied treatments, emphasizing its potential as a first-choice treatment for migraine prophylaxis.

Major finding: Among all prophylactic treatments, high-dose EPA/DHA supplementation showed the highest decrease in migraine frequency (standardized mean difference [SMD] ─1.36; 95% CI ─2.32 to ─0.39) and severity (SMD ─2.23; 95% CI ─3.17 to ─1.30) and the most favorable acceptability rate (odds ratio 1.00; 95% CI 0.06 to 17.41) compared with placebo.

Study details: The data come from a network meta-analysis of 40 randomized controlled trials that included 6616 patients with either episodic or chronic migraine.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Tseng PT et al. Efficacy of high dosage anti-inflammatory eicosapentaenoic acid/docosahexaenoic acid for migraine prophylaxis: A network meta-analysis. Adv Nutr. 2023;15(2):100163 (Dec 16). doi: 10.1016/j.advnut.2023.100163

Key clinical point: High-dose eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) supplementation demonstrated highest efficacy and acceptability among all studied treatments, emphasizing its potential as a first-choice treatment for migraine prophylaxis.

Major finding: Among all prophylactic treatments, high-dose EPA/DHA supplementation showed the highest decrease in migraine frequency (standardized mean difference [SMD] ─1.36; 95% CI ─2.32 to ─0.39) and severity (SMD ─2.23; 95% CI ─3.17 to ─1.30) and the most favorable acceptability rate (odds ratio 1.00; 95% CI 0.06 to 17.41) compared with placebo.

Study details: The data come from a network meta-analysis of 40 randomized controlled trials that included 6616 patients with either episodic or chronic migraine.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Tseng PT et al. Efficacy of high dosage anti-inflammatory eicosapentaenoic acid/docosahexaenoic acid for migraine prophylaxis: A network meta-analysis. Adv Nutr. 2023;15(2):100163 (Dec 16). doi: 10.1016/j.advnut.2023.100163

Key clinical point: The likelihood of motor vehicle crashes (MVC) in the year following diagnosis is significantly higher among older drivers who have recently been diagnosed with migraine, emphasizing the necessity for driving safety interventions for these individuals.

Major finding: The risk for an MVC in the year after migraine onset was > 3 times higher among older adult drivers with new-onset migraine compared with those who never had a migraine (adjusted odds ratio [aOR] 3.27; P = .019). Prevalent migraine was not associated with MVC in the subsequent 2 years (aOR 0.97; P = .88).

Study details: Findings are from the AAA Longitudinal Research on Aging Drivers study, which included 2589 older drivers (age 65-79 years) with a valid driver’s license, of whom 12.5% and 1.3% reported prevalent and incident migraines, respectively.

Disclosures: This study was funded by the AAA Foundation for Traffic Safety and National Center for Advancing Translational Sciences. The authors declared no conflicts of interest.

Source: DiGuiseppi CG et al. Migraine headaches are associated with motor vehicle crashes and driving habits among older drivers: Prospective cohort study. J Am Geriatr Soc. 2023 (Dec 22). doi: 10.1111/jgs.18719

Key clinical point: The likelihood of motor vehicle crashes (MVC) in the year following diagnosis is significantly higher among older drivers who have recently been diagnosed with migraine, emphasizing the necessity for driving safety interventions for these individuals.

Major finding: The risk for an MVC in the year after migraine onset was > 3 times higher among older adult drivers with new-onset migraine compared with those who never had a migraine (adjusted odds ratio [aOR] 3.27; P = .019). Prevalent migraine was not associated with MVC in the subsequent 2 years (aOR 0.97; P = .88).

Study details: Findings are from the AAA Longitudinal Research on Aging Drivers study, which included 2589 older drivers (age 65-79 years) with a valid driver’s license, of whom 12.5% and 1.3% reported prevalent and incident migraines, respectively.

Disclosures: This study was funded by the AAA Foundation for Traffic Safety and National Center for Advancing Translational Sciences. The authors declared no conflicts of interest.

Source: DiGuiseppi CG et al. Migraine headaches are associated with motor vehicle crashes and driving habits among older drivers: Prospective cohort study. J Am Geriatr Soc. 2023 (Dec 22). doi: 10.1111/jgs.18719

Key clinical point: The likelihood of motor vehicle crashes (MVC) in the year following diagnosis is significantly higher among older drivers who have recently been diagnosed with migraine, emphasizing the necessity for driving safety interventions for these individuals.

Major finding: The risk for an MVC in the year after migraine onset was > 3 times higher among older adult drivers with new-onset migraine compared with those who never had a migraine (adjusted odds ratio [aOR] 3.27; P = .019). Prevalent migraine was not associated with MVC in the subsequent 2 years (aOR 0.97; P = .88).

Study details: Findings are from the AAA Longitudinal Research on Aging Drivers study, which included 2589 older drivers (age 65-79 years) with a valid driver’s license, of whom 12.5% and 1.3% reported prevalent and incident migraines, respectively.

Disclosures: This study was funded by the AAA Foundation for Traffic Safety and National Center for Advancing Translational Sciences. The authors declared no conflicts of interest.

Source: DiGuiseppi CG et al. Migraine headaches are associated with motor vehicle crashes and driving habits among older drivers: Prospective cohort study. J Am Geriatr Soc. 2023 (Dec 22). doi: 10.1111/jgs.18719

Key clinical point: In patients with psoriatic arthritis (PsA), a high dietary acid load (DAL), evaluated through potential renal acid load (PRAL) and net endogenous acid production (NEAP), was associated with increased disease activity and inflammation.

Major finding: The mean Disease Activity Index for PsA scores were higher in patients with PsA who had high vs low PRAL (19.8 vs 14.0; P = .006) and high vs low NEAP (20.3 vs 13.5; P = .001). In addition, patients in the high vs low PRAL and NEAP groups had significantly higher C-reactive protein levels (P = .024 and P = .020, respectively), indicating increased inflammation.

Study details: Findings are from a cross-sectional study that included 58 patients with overweight or obesity and a diagnosis of PsA.

Disclosures: This study did not disclose any funding. The authors declared no conflicts of interest.

Source: Öteleş S et al. The dietary acid load is associated with disease severity in psoriatic arthritis. Mod Rheumatol. 2023 (Nov 10). doi: 10.1093/mr/road107

Key clinical point: In patients with psoriatic arthritis (PsA), a high dietary acid load (DAL), evaluated through potential renal acid load (PRAL) and net endogenous acid production (NEAP), was associated with increased disease activity and inflammation.

Major finding: The mean Disease Activity Index for PsA scores were higher in patients with PsA who had high vs low PRAL (19.8 vs 14.0; P = .006) and high vs low NEAP (20.3 vs 13.5; P = .001). In addition, patients in the high vs low PRAL and NEAP groups had significantly higher C-reactive protein levels (P = .024 and P = .020, respectively), indicating increased inflammation.

Study details: Findings are from a cross-sectional study that included 58 patients with overweight or obesity and a diagnosis of PsA.

Disclosures: This study did not disclose any funding. The authors declared no conflicts of interest.

Source: Öteleş S et al. The dietary acid load is associated with disease severity in psoriatic arthritis. Mod Rheumatol. 2023 (Nov 10). doi: 10.1093/mr/road107

Key clinical point: In patients with psoriatic arthritis (PsA), a high dietary acid load (DAL), evaluated through potential renal acid load (PRAL) and net endogenous acid production (NEAP), was associated with increased disease activity and inflammation.

Major finding: The mean Disease Activity Index for PsA scores were higher in patients with PsA who had high vs low PRAL (19.8 vs 14.0; P = .006) and high vs low NEAP (20.3 vs 13.5; P = .001). In addition, patients in the high vs low PRAL and NEAP groups had significantly higher C-reactive protein levels (P = .024 and P = .020, respectively), indicating increased inflammation.

Study details: Findings are from a cross-sectional study that included 58 patients with overweight or obesity and a diagnosis of PsA.

Disclosures: This study did not disclose any funding. The authors declared no conflicts of interest.

Source: Öteleş S et al. The dietary acid load is associated with disease severity in psoriatic arthritis. Mod Rheumatol. 2023 (Nov 10). doi: 10.1093/mr/road107

Key clinical point: The risk for late-onset psoriatic arthritis (PsA) was higher in women who attained early natural menopause and had shorter reproductive years.

Major finding: The risk for incident PsA reduced by 46% and 34% in women who reached natural menopause at ≥55 vs <45 years of age and had a reproductive lifespan of ≥38 vs <38 years, respectively (P ≤ .006 for all). The partial population-attributable risk estimated that approximately 1/5of late-onset PsA incidences could be prevented if women went through menopause after the age of 55 years.

Study details: This prospective cohort study included postmenopausal women without psoriatic diseases from the UK Biobank, who were investigated for incident psoriasis (n = 139,572) or PsA (n = 142,329).

Disclosures: This study was supported by the National Natural Science Foundation of China and the Huxiang Youth Talent Supporting Program of Hunan. The authors declared no conflicts of interest.

Source: Xiao Y et al. Age at natural menopause, reproductive lifespan and the risk of late-onset psoriasis and psoriatic arthritis in women: A prospective cohort study. J Invest Dermatol. 2023 (Dec 9). doi: 10.1016/j.jid.2023.11.010

Key clinical point: The risk for late-onset psoriatic arthritis (PsA) was higher in women who attained early natural menopause and had shorter reproductive years.

Major finding: The risk for incident PsA reduced by 46% and 34% in women who reached natural menopause at ≥55 vs <45 years of age and had a reproductive lifespan of ≥38 vs <38 years, respectively (P ≤ .006 for all). The partial population-attributable risk estimated that approximately 1/5of late-onset PsA incidences could be prevented if women went through menopause after the age of 55 years.

Study details: This prospective cohort study included postmenopausal women without psoriatic diseases from the UK Biobank, who were investigated for incident psoriasis (n = 139,572) or PsA (n = 142,329).

Disclosures: This study was supported by the National Natural Science Foundation of China and the Huxiang Youth Talent Supporting Program of Hunan. The authors declared no conflicts of interest.

Source: Xiao Y et al. Age at natural menopause, reproductive lifespan and the risk of late-onset psoriasis and psoriatic arthritis in women: A prospective cohort study. J Invest Dermatol. 2023 (Dec 9). doi: 10.1016/j.jid.2023.11.010

Key clinical point: The risk for late-onset psoriatic arthritis (PsA) was higher in women who attained early natural menopause and had shorter reproductive years.

Major finding: The risk for incident PsA reduced by 46% and 34% in women who reached natural menopause at ≥55 vs <45 years of age and had a reproductive lifespan of ≥38 vs <38 years, respectively (P ≤ .006 for all). The partial population-attributable risk estimated that approximately 1/5of late-onset PsA incidences could be prevented if women went through menopause after the age of 55 years.

Study details: This prospective cohort study included postmenopausal women without psoriatic diseases from the UK Biobank, who were investigated for incident psoriasis (n = 139,572) or PsA (n = 142,329).

Disclosures: This study was supported by the National Natural Science Foundation of China and the Huxiang Youth Talent Supporting Program of Hunan. The authors declared no conflicts of interest.

Source: Xiao Y et al. Age at natural menopause, reproductive lifespan and the risk of late-onset psoriasis and psoriatic arthritis in women: A prospective cohort study. J Invest Dermatol. 2023 (Dec 9). doi: 10.1016/j.jid.2023.11.010

Key clinical point: Poor sleep quality was a very common phenomenon in patients with psoriatic arthritis (PsA) and associated with increased disease activity and higher levels of pain, fatigue, anxiety, and depression.

Major finding: A majority (63%) of patients with PsA experienced poor sleep quality, with factors like higher Disease Activity Index for PsA scores, pain, fatigue, anxiety, and depression (P < .01 for all) associated with poorer sleep quality. Patients with vs without fibromyalgia also reported poorer sleep quality (P < .001).

Study details: Findings are from a single-center cross-sectional study that included 247 patients with PsA.

Disclosures: This study received medical writing/editorial assistance from the Spanish Foundation of Rheumatology. The authors declared no conflicts of interest.

Source: Toledano E et al. SLEEP quality in patients with psoriatic arthritis and its relationship with disease activity and comorbidities: A cross-sectional study. Sci Rep. 2023;13:22927 (Dec 21). doi: 10.1038/s41598-023-48723-z

Key clinical point: Poor sleep quality was a very common phenomenon in patients with psoriatic arthritis (PsA) and associated with increased disease activity and higher levels of pain, fatigue, anxiety, and depression.

Major finding: A majority (63%) of patients with PsA experienced poor sleep quality, with factors like higher Disease Activity Index for PsA scores, pain, fatigue, anxiety, and depression (P < .01 for all) associated with poorer sleep quality. Patients with vs without fibromyalgia also reported poorer sleep quality (P < .001).

Study details: Findings are from a single-center cross-sectional study that included 247 patients with PsA.

Disclosures: This study received medical writing/editorial assistance from the Spanish Foundation of Rheumatology. The authors declared no conflicts of interest.

Source: Toledano E et al. SLEEP quality in patients with psoriatic arthritis and its relationship with disease activity and comorbidities: A cross-sectional study. Sci Rep. 2023;13:22927 (Dec 21). doi: 10.1038/s41598-023-48723-z

Key clinical point: Poor sleep quality was a very common phenomenon in patients with psoriatic arthritis (PsA) and associated with increased disease activity and higher levels of pain, fatigue, anxiety, and depression.

Major finding: A majority (63%) of patients with PsA experienced poor sleep quality, with factors like higher Disease Activity Index for PsA scores, pain, fatigue, anxiety, and depression (P < .01 for all) associated with poorer sleep quality. Patients with vs without fibromyalgia also reported poorer sleep quality (P < .001).

Study details: Findings are from a single-center cross-sectional study that included 247 patients with PsA.

Disclosures: This study received medical writing/editorial assistance from the Spanish Foundation of Rheumatology. The authors declared no conflicts of interest.

Source: Toledano E et al. SLEEP quality in patients with psoriatic arthritis and its relationship with disease activity and comorbidities: A cross-sectional study. Sci Rep. 2023;13:22927 (Dec 21). doi: 10.1038/s41598-023-48723-z